Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Philipp Klyscz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-…. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Receptors, Interleukin-2, Myelin-Oligodendrocyte Glycoprotein. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions. Here, we compared sIL‐2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin‐4‐IgG‐seropositive and seronegative (AQP4‐IgG+/−) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL‐2R for future attacks.
Methods
Retrospective analysis of real‐world data of patients treated at Charité—Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4‐IgG+NMOSD, 10 AQP4‐IgG−NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow‐up time was 40 (35) months. sIL‐2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks.
Results
Serum sIL‐2R was higher in AQP4‐IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL‐2R (HR = 9.07 [95% CI 1.37–60.01]) and CSF sIL‐2R (HR = 3.27 [95% CI 0.61–17.45]) levels were predictive for subsequent attacks.
Interpretation
Serum sIL‐2R is elevated in AQP4‐IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Neuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Division of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
- Labor Berlin Charité-Vivantes GmbH, Berlin, Germany.
ORCID-Profile: Philipp Klyscz, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Friedemann Paul, Patrick Schindler
Zitieren
APA
Klyscz, P., Otto, C., Ruprecht, K., Asseyer, S., Tiedt, H. O., Meisel, C., Bellmann-Strobl, J., Paul, F., & Schindler, P. (2025). Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70186
Vancouver
Klyscz P, Otto C, Ruprecht K, Asseyer S, Tiedt HO, Meisel C, et al. Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70186
BibTeX
@article{Klyscz2025,
author = {Klyscz, Philipp and Otto, Carolin and Ruprecht, Klemens and Asseyer, Susanna and Tiedt, Hannes Ole and Meisel, Christian and Bellmann-Strobl, Judith and Paul, Friedemann and Schindler, Patrick},
title = {Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70186}
}
EUVIMED